Trastuzumab

Journal of Clinical Oncology P

11 years ago

Adjuvant Trastuzumab Passes the Test of Time

positive

cancer

breast

adjuvant

trastuzumab

+5

+4

+3

+3

+2

+2

+1

+1

positive

cancer

breast

adjuvant

trastuzumab

+5

+4

+3

+3

+2

+2

+1

+1

The Lancet: July 18, 2013

Listen to The Lancet

13 years ago

The Lancet: July 18, 2013

breast cancer

trastuzumab

herceptin

her2

radiotherapy

+5

+5

+4

+4

+3

+3

+2

+2

06:56

breast cancer

trastuzumab

herceptin

her2

radiotherapy

+5

+5

+4

+4

+3

+3

+2

+2

Journal of Clinical Oncology P

15 years ago

Trastuzumab in the Adjuvant Setting - Sequential versus Concurrent: Will We Ever Know the Full Answe

breast

sequential

concurrent

adjuvant

trastuzumab

+4

+4

+4

+3

+3

+2

+2

+1

breast

sequential

concurrent

adjuvant

trastuzumab

+4

+4

+4

+3

+3

+2

+2

+1

Cheaper breast cancer therapy

Health Report - Separate stori

9 years ago

Cheaper breast cancer therapy

breast cancer

trastuzumab

herceptin

biosimilar

survival

+5

+5

+4

+4

+3

+3

+2

+2

07:03

breast cancer

trastuzumab

herceptin

biosimilar

survival

+5

+5

+4

+4

+3

+3

+2

+2

The Lancet Oncology: March 01, 2011

Listen to The Lancet Oncology

15 years ago

The Lancet Oncology: March 01, 2011

breast cancer

herceptin

trastuzumab

her2 breast cancer

monoclonal antibody

+5

+5

+4

+4

+3

+3

+2

+2

+1

breast cancer

herceptin

trastuzumab

her2 breast cancer

monoclonal antibody

+5

+5

+4

+4

+3

+3

+2

+2

+1

Journal of Clinical Oncology P

14 years ago

1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting

neoadjuvant

lapatinib

trastuzumab

her2

+4

+3

+3

+2

+2

+2

neoadjuvant

lapatinib

trastuzumab

her2

+4

+3

+3

+2

+2

+2

Journal of Clinical Oncology P

13 years ago

Who Needs What Therapy? The Elusive Search for Predictive Markers

prediction

prognosis

trastuzumab

pten

her2

+5

+4

+4

+3

+3

+3

+2

+1

prediction

prognosis

trastuzumab

pten

her2

+5

+4

+4

+3

+3

+3

+2

+1

Journal of Clinical Oncology P

13 years ago

Long Term Follow-up of NSABP B-31: How Well Can We Predict Cardiac Toxicity with Trastuzumab?

trastuzumab

her2

cardiactoxicity

+3

+2

+2

+1

+1

trastuzumab

her2

cardiactoxicity

+3

+2

+2

+1

+1

The Lancet Oncology: August 06, 2012

Listen to The Lancet Oncology

14 years ago

The Lancet Oncology: August 06, 2012

oncology

her2

trastuzumab

medicine

science

+5

+4

+3

+3

+3

+2

+2

+1

oncology

her2

trastuzumab

medicine

science

+5

+4

+3

+3

+3

+2

+2

+1